Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Döhner H, Wei AH, Roboz GJ, Montesinos P, Thol FR, Ravandi F, Dombret H, Porkka K, Sandhu I, Skikne B, See WL, Ugidos M, Risueño A, Chan ET, Thakurta A, Beach CL, Lopes de Menezes D.
Döhner H, et al. Among authors: beach cl.
Blood. 2022 Oct 13;140(15):1674-1685. doi: 10.1182/blood.2022016293.
Blood. 2022.
PMID: 35960871
Free PMC article.
Clinical Trial.